Breaking News, Collaborations & Alliances

Sanyou, Sinorda Partner to Advance Bispecific Antibody Drug Development

Will leverage Sanyou's core technology R&D platform and Sinorda's experience in preclinical and clinical oncology immunotherapy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanyou Biopharmaceuticals and Sinorda Biomedicine entered into a strategic cooperation agreement to advance innovative bispecific antibody drug development. The collaboration will leverage Sanyou’s core technology platform for integrated R&D and preclinical development and “super-trillion innovative biologics discovery platform”, and Sinorda’s experience in preclinical and clinical oncology immunotherapy. Pingsheng Hu, CEO of Sinorda, said, “Sinorda focuse...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters